72,648 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Bought by TD Asset Management Inc

TD Asset Management Inc acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 72,648 shares of the biopharmaceutical company’s stock, valued at approximately $5,203,000. TD Asset Management Inc owned about 0.08% of Intra-Cellular Therapies at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ITCI. Barclays PLC grew its stake in Intra-Cellular Therapies by 51.5% during the 3rd quarter. Barclays PLC now owns 63,688 shares of the biopharmaceutical company’s stock worth $3,318,000 after buying an additional 21,643 shares during the last quarter. Quantbot Technologies LP boosted its position in Intra-Cellular Therapies by 22.5% during the 3rd quarter. Quantbot Technologies LP now owns 10,602 shares of the biopharmaceutical company’s stock worth $552,000 after acquiring an additional 1,946 shares during the period. Oppenheimer Asset Management Inc. boosted its position in Intra-Cellular Therapies by 9.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 34,424 shares of the biopharmaceutical company’s stock worth $1,793,000 after acquiring an additional 2,969 shares during the period. Swiss National Bank boosted its position in Intra-Cellular Therapies by 1.7% during the 3rd quarter. Swiss National Bank now owns 189,800 shares of the biopharmaceutical company’s stock worth $9,887,000 after acquiring an additional 3,100 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in Intra-Cellular Therapies by 36.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 974,914 shares of the biopharmaceutical company’s stock worth $50,783,000 after acquiring an additional 259,424 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on ITCI. Canaccord Genuity Group boosted their price target on Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Mizuho boosted their price target on Intra-Cellular Therapies from $82.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, April 22nd. TD Cowen upped their price objective on Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Intra-Cellular Therapies in a report on Tuesday, May 7th. Finally, Bank of America upped their price objective on Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and an average price target of $92.73.

View Our Latest Stock Analysis on ITCI

Insider Activity

In related news, CEO Sharon Mates sold 20,565 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the transaction, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at $68,490,649.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Sharon Mates sold 20,565 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the transaction, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at $68,490,649.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Lawrence J. Hineline sold 10,121 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.96, for a total value of $667,581.16. The disclosure for this sale can be found here. Insiders sold a total of 38,031 shares of company stock valued at $2,493,174 over the last three months. Insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Stock Down 0.1 %

Shares of NASDAQ ITCI opened at $67.81 on Thursday. Intra-Cellular Therapies, Inc. has a 12 month low of $45.50 and a 12 month high of $84.89. The company has a market cap of $7.16 billion, a price-to-earnings ratio of -58.46 and a beta of 0.97. The business has a fifty day simple moving average of $68.78 and a 200-day simple moving average of $67.79.

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The business had revenue of $144.90 million during the quarter, compared to the consensus estimate of $141.41 million. During the same period in the prior year, the business posted ($0.46) earnings per share. Intra-Cellular Therapies’s revenue was up 52.0% compared to the same quarter last year. As a group, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.53 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

(Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Recommended Stories

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.